Medtronic concluded its spin-off of MiniMed in October.
Investors will expect rising sales and stabilizing margins in its upcoming report.
Medtronic (NYSE:MDT), one of the world's largest medical device makers, will post its next earnings report on Nov. 24. It will mark its first earnings report after it spun off its diabetes unit, MiniMed (NASDAQ:MMED), and fully removed its business from its balance sheet.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
In fiscal 2023 and fiscal 2024 (which ended in April 2024), Medtronic's earnings declined as it struggled with supply chain constraints, inflation, forex headwinds, regulatory challenges for its diabetes business, and lumpy post-pandemic recovery in elective procedures. Tougher competition, quality control issues, and new GLP-1 drugs exacerbated that pressure.
But in fiscal 2025 and fiscal 2026, its earnings grew again as it stabilized its costs, expanded its higher-growth cardiovascular and neuroscience businesses, and spun off MiniMed. In fiscal 2026, its revenue grew 5.8% organically, marking its strongest top-line growth in a decade. For fiscal 2027, it expects its revenue to rise another 7.25%-7.75%.
For the third quarter of fiscal 2027, analysts expect Medtronic's revenue to rise 6% year over year but for its adjusted EPS to dip 2%. Its cardiovascular and neuroscience businesses should remain strong. Still, the completion of its MiniMed spin-off (which concluded on Oct. 15), its reinvestment in higher-growth platforms, early-stage manufacturing costs for newer cardiovascular devices, and a few recent acquisitions are squeezing its margins.
Medtronic's stock looks cheap at 17 times forward earnings and pays a forward yield of 2.9%. However, I'd wait to see how well it grows organically -- and how it's handling the margin pressure -- before buying the stock and assuming it's a safe blue chip dividend play.
Before you buy stock in Medtronic, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Medtronic. The Motley Fool has a disclosure policy.